Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 15

423P - Marginalization and factors associated with early mortality among patients diagnosed with de novo metastatic breast cancer in Ontario, Canada

Date

14 Sep 2024

Session

Poster session 15

Topics

Population Risk Factor;  Primary Prevention;  Cancer Care Equity Principles and Health Economics;  Cancer Epidemiology;  Cancer Research

Tumour Site

Breast Cancer

Presenters

Priya Thomas

Citation

Annals of Oncology (2024) 35 (suppl_2): S357-S405. 10.1016/annonc/annonc1579

Authors

P. Thomas1, B. Carter2, C. Earle3, S. Sharriff2, J. Raphael4, A. Mahar5, S. Knowles6, M. brackstone6, M. Lock7, A. Eisen3, P. Blanchette4

Author affiliations

  • 1 Department Of Medicine, University of Western Ontario, N6A 3K7 - London/CA
  • 2 Ices, Institute for Clinical Evaluative Sciences, M4N 3M5 - Toronto/CA
  • 3 Division Of Medical Oncology, Sunnybrook Health Sciences Centre - Odette Cancer Centre, M4N 3M5 - Toronto/CA
  • 4 Division Of Medical Oncology, London Regional Cancer Program (LRCP) - London Health Science Center (LHSC), N6A 4L6 - London/CA
  • 5 Division Of Cancer Care And Epidemiology, Queen's Cancer Research Institute (QCRI), K7L 3N6 - Kingston/CA
  • 6 Division Of General Surgery, London Health Sciences Centre, N6A 5W9 - London/CA
  • 7 Division Of Radiation Oncology, London Health Sciences Centre, N6A 5W9 - London/CA

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 423P

Background

In Ontario, breast cancer affects 1 in 9 women and 2000 women die from breast cancer annually. Early death from breast cancer is uncommon and may be influenced by factors such as biology, age, marginalization, socioeconomic status, and rurality. Our objective was to investigate factors associated with early mortality from advanced de novo metastatic breast cancer in a publicly funded health care system.

Methods

We used linked healthcare administrative data from 2010-2019 to determine the frequency of early mortality, defined as death within 6 months of cancer diagnosis, from de novo metastatic breast cancer. A multivariable logistic regression model was used to determine which patient, cancer, and provider characteristics may be associated with early mortality. The Ontario Marginalization Index, a census and geographically based tool evaluating economic, ethno-racial, age-based and social marginalization, was used.

Results

We identified 4,004 patients with de novo metastatic breast cancer, of whom 22.9% (N=918) experienced early mortality (death within 6 months). Multivariable regression revealed that advanced age and a high marginalization index score (HMIS) were significantly associated with early mortality. [HMIS odd ratio vs low marginalization index score (LMIS) (OR)=1.48, 95% confidence interval (CI)=1.17-1.88, p-value=0.001]. Registration with a family physician was associated with significant decreased risk of early mortality (OR=0.74, 95%CI=0.62-0.89, p-value<0.001). There was variability in early mortality across geographic regions of the province and rurality did not affect early mortality until patients received treatment. Treatment with chemotherapy alone (typically used in triple-negative breast cancer) had higher odds of early mortality. Provider characteristics and acuity of the cancer center were not associated with early mortality.

Conclusions

The results of this study suggest that factors such as marginalization, access to a family physician, and geography play a role in early mortality from breast cancer in the setting of a publicly funded health care system. Improving access to a family physician may help to reduce early breast cancer mortality.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Patient donor.

Disclosure

J. Raphael: Financial Interests, Personal, Advisory Role: Eli Lilly, Merck; Financial Interests, Personal, Advisory Board: Novartis, Roche. M. Lock: Financial Interests, Personal, Advisory Role: Bayer, Abbvie, Tolmar, Eisai, Ferring, Tersera. A. Eisen: Financial Interests, Personal, Project Lead: Ontario Health Breast Cancer Disease Site ; Financial Interests, Personal, Research Funding: RNA diagnostics. P. Blanchette: Financial Interests, Personal, Advisory Role: Canada’s Drug and Health Technology Agency. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.